Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...

BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has commended Nanomerics for the successful completion of a human ...

When Vijay Sankaran was an MD-PhD student at Harvard Medical School in the mid-2000s, one of his first clinical encounters ...

The stock's rise snapped a four-day losing streak.

Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

The committee supports approving the CFTR modulator for patients 2 years and older with at least one non-class I CFTR gene mutation.

Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...

Alltrna’s CEO Michelle Warner said that the approach allows for basket trials that can group patients with different diseases ...

Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited “changing priorities.” ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alphatec Holdings (ATEC – Research Report), Vertex ...